Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6B
|
| pubmed:dateCreated |
1993-4-9
|
| pubmed:abstractText |
In contrast to the situation in invasive breast carcinoma, there are only few reports on the levels of receptors for estrogen (ER) and progesterone (PgR) in pre-invasive (in situ) breast carcinoma. In the present study ER and PgR levels were analyzed in 57 in situ human mammary carcinomas using a quantitative enzyme immunoassay method. Intraductal carcinoma was the dominating histopathological subgroup (75%). Within this subgroup the non-comedo and comedo variants comprised 66 and 34 percent respectively. Intralobular and papillary in situ subtypes were the second most frequent subgroups, representing 11% each. Using a cut-off level of 0.05 fmole/microgram DNA to define receptor poor and rich tumors we found that thirty-one out of the 57 cases (54%) were ER-rich. In the ER-rich tumors the receptor levels varied between 0.05 and 6.50 fmole/microgram with a mean concentration of 0.80 fmole/microgram DNA. Fifteen of 51 (30%) tumors were classified as PgR-rich tumors in which the levels ranged between 0.05 and 2.90 fmoles/microgram DNA, with a mean concentration of 0.45 fmoles/microgram DNA. Two thirds of the non-comedo, lobular and papillary variant were ER rich. A majority (80%) of comedo tumors were ER poor. Our findings show that 54% of in situ breast carcinomas have the molecular prerequisites for response to antiestrogen therapy which is of interest when planning adjuvant treatment protocols.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0250-7005
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
12
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2113-5
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:1295456-Breast Neoplasms,
pubmed-meshheading:1295456-Carcinoma in Situ,
pubmed-meshheading:1295456-DNA, Neoplasm,
pubmed-meshheading:1295456-Estrogen Antagonists,
pubmed-meshheading:1295456-Female,
pubmed-meshheading:1295456-Humans,
pubmed-meshheading:1295456-Immunoenzyme Techniques,
pubmed-meshheading:1295456-Prognosis,
pubmed-meshheading:1295456-Receptors, Estrogen,
pubmed-meshheading:1295456-Receptors, Progesterone,
pubmed-meshheading:1295456-Retrospective Studies
|
| pubmed:articleTitle |
Receptors for estrogen and progesterone in breast carcinoma in situ.
|
| pubmed:affiliation |
Department of Surgery, Karolinska Hospital, Stockholm, Sweden.
|
| pubmed:publicationType |
Journal Article
|